{
  "id": "apheresis",
  "title": "Apheresis",
  "lang": "en",
  "source_lang": "en",
  "summary": "Apheresis is a procedure that separates blood into components, selectively collecting, removing, or treating one component while returning the remainder to the circulation.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Hemapheresis",
    "Haemapheresis"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/apheresis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/apheresis/",
      "json": "https://aiwiki.page/zh/apheresis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Apheresis is a medical procedure in which blood is withdrawn from a donor or patient, separated into components outside the body, and selectively collected, removed, exchanged, or treated before the remaining blood is returned to the circulation. It is used both to obtain blood products for transfusion or cellular therapies and to treat diseases involving abnormal blood cells or substances circulating in plasma. The term describes a family of procedures rather than a single treatment."
    },
    {
      "heading": "Principles and equipment",
      "text": "Blood consists of plasma, its liquid component, and cellular elements: red blood cells, white blood cells, and platelets. Apheresis equipment separates these components primarily by one of two methods:\n\n- Centrifugation: spinning separates components according to differences in density. This method can collect or remove plasma, platelets, red cells, or selected white-cell fractions.\n- Membrane filtration: blood passes through a membrane that separates plasma from blood cells. Additional filters or adsorption devices can selectively remove substances from the separated plasma.\n\nBlood travels through a sterile, usually single-use extracorporeal circuit. An anticoagulant prevents clotting within the tubing and separation device. Citrate, which binds ionized calcium, is commonly used; some systems use heparin.\n\nProcedures may operate with continuous flow or intermittent withdrawal and return. Access is usually through peripheral veins or, when necessary, a central venous catheter. The choice depends on the procedure, required blood flow, and available venous access.\n\nApheresis differs from hemodialysis, which primarily removes small dissolved substances and excess water across a dialysis membrane. Although both circulate blood outside the body, their separation mechanisms and principal targets differ."
    },
    {
      "heading": "Collection apheresis",
      "text": "Collection apheresis obtains a particular component while returning much of the remaining blood to the donor or patient.\n\nPlatelet and plasma collection\n\nPlateletpheresis collects platelets for transfusion, including support for people with low platelet counts resulting from chemotherapy or bone-marrow disorders. Automated collection can obtain a therapeutic platelet dose from a single donor, reducing the number of donor exposures compared with some pooled platelet products.\n\nPlasmapheresis separates and collects plasma. Donor plasma may be prepared for transfusion or used as starting material for manufacturing medicines such as immunoglobulins and coagulation-factor products. In this collection setting, blood cells are returned to the donor.\n\nThe word plasmapheresis is sometimes used loosely for therapeutic plasma exchange, but the terms are not strictly interchangeable: plasma collection does not necessarily involve exchanging a large volume of plasma with replacement fluid.\n\nRed-cell and granulocyte collection\n\nErythrocytapheresis selectively collects or removes red blood cells. Donation systems can collect red-cell units while returning plasma and other components.\n\nGranulocytapheresis collects granulocytes, a group of white blood cells. Granulocyte transfusions have specialized, limited uses in selected patients with severe neutropenia or impaired granulocyte function and serious infection.\n\nCells for transplantation and cellular therapy\n\nApheresis can collect circulating blood-forming progenitor cells for hematopoietic stem cell transplantation. These cells are often mobilized from the bone marrow into peripheral blood before collection.\n\nCollection of mononuclear cells, including lymphocytes, also supplies starting material for cellular therapies. For example, CAR T-cell therapy commonly begins with leukapheresis to collect cells from which T cells are obtained and subsequently modified."
    },
    {
      "heading": "Therapeutic apheresis",
      "text": "Therapeutic apheresis aims to remove harmful circulating material, replace abnormal blood components, or modify selected cells. Its usefulness depends on the disease mechanism, how readily the target can be removed from the circulation, and whether it is rapidly regenerated or redistributed from tissues.\n\nTherapeutic plasma exchange\n\nTherapeutic plasma exchange removes a substantial volume of a patient’s plasma and replaces it with an appropriate fluid, commonly albumin solution, donor plasma, or a combination determined by the condition.\n\nPlasma exchange is relatively nonselective. It can remove disease-associated antibodies, abnormal proteins, and other plasma constituents, but it also removes useful proteins and some circulating medicines.\n\nEstablished applications include:\n\n- Immune-mediated thrombotic thrombocytopenic purpura: plasma exchange removes circulating inhibitors of the enzyme ADAMTS13 while donor plasma supplies functional enzyme.\n- Guillain–Barré syndrome: plasma exchange is an established treatment in appropriate clinical settings.\n- Myasthenia gravis: plasma exchange can produce relatively rapid, temporary improvement in selected circumstances, including myasthenic crisis.\n- Certain antibody-mediated kidney and systemic disorders: use depends on the specific diagnosis and clinical circumstances.\n\nThese applications are disease-specific. The presence of an autoantibody or a diagnosis of autoimmune disease alone does not establish that plasma exchange is effective.\n\nRed-cell exchange\n\nRed-cell exchange removes a patient’s red cells and replaces them with donor red cells. In sickle cell disease, it reduces the proportion of circulating sickle hemoglobin. Automated exchange can achieve this while controlling hematocrit and limiting net iron accumulation compared with repeated simple transfusions, although iron balance depends on the exchange prescription and prior transfusion history.\n\nWhite-cell and platelet depletion\n\nLeukapheresis can remove circulating white blood cells in selected patients with marked leukocytosis, particularly when associated with leukostasis in leukemia. It does not treat the underlying malignant clone and is not a substitute for disease-directed therapy. Evidence for improved clinical outcomes varies by setting.\n\nTherapeutic plateletpheresis, or thrombocytapheresis, can rapidly reduce extremely elevated platelet counts in selected urgent situations. Its effect is temporary because platelet production continues.\n\nSelective removal and cell treatment\n\nLipoprotein apheresis removes circulating atherogenic lipoproteins in selected severe lipid disorders. Different systems use adsorption, filtration, or precipitation.\n\nImmunoadsorption passes separated plasma through a device designed to bind immunoglobulins or other selected targets. Compared with plasma exchange, it can preserve more of the plasma’s other constituents, depending on the system.\n\nExtracorporeal photopheresis collects a white-cell-rich fraction, exposes it to a photosensitizing agent and ultraviolet A light, and returns the treated cells. It is used in conditions including cutaneous T-cell lymphoma and selected cases of graft-versus-host disease. Its purpose is immune modulation rather than simple removal of a blood component."
    },
    {
      "heading": "Risks and limitations",
      "text": "Adverse effects depend on the procedure, replacement fluid, vascular access, treatment frequency, and the person’s underlying condition.\n\nCitrate can temporarily lower ionized calcium, causing tingling, muscle cramps, or other symptoms; more pronounced disturbances can affect cardiac function. Changes in circulating volume may cause low blood pressure, dizziness, or nausea. Reactions to donor plasma or other replacement fluids can include allergic reactions, occasionally severe.\n\nCentral venous catheters introduce risks of bleeding, infection, and thrombosis. Mechanical complications such as hemolysis are uncommon but possible. Repeated procedures can alter blood-cell counts, iron stores, immunoglobulin concentrations, or proteins involved in blood coagulation, depending on what is collected or removed.\n\nTherapeutic effects may be short-lived. A substance removed from plasma can re-enter the circulation from tissues or be produced again. Plasma exchange can also remove medicines, particularly those largely confined to the bloodstream and strongly bound to plasma proteins."
    },
    {
      "heading": "Evidence and clinical role",
      "text": "Apheresis is a technical platform whose benefits cannot be generalized across diseases. Some applications are established components of care; others are supported by limited evidence or remain investigational. Professional guidance evaluates individual indications according to their clinical role and the strength of supporting evidence.\n\nA fall in an antibody level, cell count, or another biomarker does not by itself demonstrate improved survival, function, or symptoms. Assessment therefore distinguishes the immediate efficiency of component removal from clinically meaningful outcomes."
    }
  ],
  "links": [
    "blood-transfusion",
    "platelet",
    "chemotherapy",
    "neutropenia",
    "hematopoietic-stem-cell-transplantation",
    "bone-marrow",
    "car-t-cell-therapy",
    "antibody",
    "myasthenia-gravis",
    "autoimmune-disease",
    "sickle-cell-disease",
    "leukemia",
    "graft-versus-host-disease",
    "nausea",
    "allergy",
    "thrombosis",
    "hemolysis",
    "biomarker"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}